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Summary The pathophysiology of Raynaud's phenomenon after Cisplatin-Bleomycin-Vinblastine combina-
tion chemotherapy, its relationship to polyneuropathy, and response to transcutaneous nerve stimulation
(TNS), was studied in eight patients previously treated for testicular cancer. Peripheral circulation in the index
finger was measured by laser Doppler flowmetry before and after cold provocation. In all patients there was
an exaggerated and prolonged vasoconstrictor response to cold, with a mean flux reduction of 61%, and a
mean restitution time of >7 min, characteristic of Raynaud's phenomenon of the vasospastic type. The
normal controls had a mean flux reduction of 24% and a restitution time of 1.5 min. Clinical examination and
nerve conduction measurements revealed a mild polyneuropathy in five of the eight patients, but an etiological
relationship with Raynaud's phenomenon could not be ascertained. There was no measurable effect of TNS.
During the last decade modern cytostatic treatment has im-
proved the survival of patients with testicular cancer drama-
tically. Most often a combination of cisplatin, bleomycin and
vinblastin (CVB) or VP16 is given.
As a consequence of the improved survival, attention has
been focused on late complications and sequelae, of which
neurological symptoms are among the most frequent. Poly-
neuropathies may develop during the treatment, and are
usually considered to be caused by vinblastin, cisplatinum or
a combined effect of both drugs (Casey et al., 1973; Kaplan
& Wiernik, 1982; Hansen et al., 1989; Thompson et al., 1984;
Roelofs et al., 1984).
An increased frequency of Raynaud's phenomenon after
chemotherapy for testicular cancer has also been noted
(Hansen & Olsen, 1989; Vogelzang et al., 1981; Vogelzang et
al., 1985). Raynaud's phenomenon usually appears at a later
stage than the polyneuropathies, about 3-6 months after
chemotherapy, and often persists for several years with no
apparent improvement. The mechanism behind the develop-
ment of Raynaud's phenomenon in these patients is un-
known, and it has not been ascertained which drug is the
responsible agent. However, most authors agree that bleo-
mycin is the most likely ethiological factor, possibly with an
enhancing additional effect of vinblastin and cisplatinum.
The aim of the present pilot study was to clarify the
pathophysiology of Raynaud's phenomenon in combination
chemotherapy by measuring the peripheral circulation in the
fingers by an objective method, and to evaluate a possible
relationship between Raynaud's phenomenon and poly-
neuropathy.
As transcutaneous nerve stimulation (TNS) is reported to
have had beneficial effect in some cases of Raynaud's pheno-
menon (Kaada, 1982; Kaada et al., 1984), we also wanted to
see if this could have any measurable effect in our patients.
Patients and methods
The patients were recruited from a questionnaire study of
patients who had received cisplatin based combination
chemotherapy (CVB) during the period 1978-1982, with no
evidence of disease for at least 3 years (Aass et al., 1990). In
the questionnaire study 33 of 72 patients reported Raynaud's
phenomenon and 19 reported symptoms of sensory poly-
neuropathy. Of the 33 patients who claimed to have white
fingers on exposure to cold, with 6r without additional symp-
toms of polyneuropathy, eight patients were living within a
travelling distance of 2 h and were recruited for the study.
Their mean age was 41 years (range 24-61).
The patients were interviewed and given a complete neuro-
logical examination with main emphasis on symptoms of
polyneuropathy.
Peripheral circulation
The peripheral circulation in the fingers was measured by
laser Doppler technique (Nilsson et al., 1980; Salerud et al.,
1983; Low et al., 1983). A 2 mW helium neon laser flowmeter
was used (Periflux, Perimed, Sweden), operating at a wave-
length of 632.8 nm. The laser probe was fastened to the pulp
of the index finger, with the laser beam penetrating to the
dermal capillaries, where the movement of the blood cells
cause a 'Doppler shift' of the reflected laser light. The 'Dop-
pler shift' as an expression of the peripheral circulation, is
measured in relative 'flux units'. At Periflux gain 1 and full
flowmeter deflection, the relative flux was defined as 100. The
recording was performed with gain x 3 and full flowmeter
deflection at relative flux 33.3. The laser doppler registration
was performed in a draught-free room at a constant temper-
ature of 23'C. After 15-20 min to obtain stable conditions,
baseline flux and temperature were measured. A 'cold pro-
vocation test' was then performed. The hand was submersed
in water at 15°C for 2 min, followed by further laser doppler
registration until the circulation returned to stable baseline-or
was stabilised at some other level.
Control
Laser Doppler measurements were also performed on 14
healthy men, mean age 32 (range 24-46), with no history of
Raynaud's phenomenon, and on four patients who had been
given surgical and radiation therapy for testicular cancer in
the period 1978-1982, but who had not received chemo-
therapy.
TNS treatment
Patients with a flux reduction of >50% received low fre-
quency TNS treatment for 25 min before cold provocation
with laser Doppler registration was repeated. TNS was per-
formed with a CEFAR stimulator giving 100 Hz square
pulses at a frequency of 2 Hz, with a stimulus intensity three
times the perception threshold, applied with a cutaneous
surface electrode at the 1.dorsal interosseum of the right
hand. They were also given a TNS stimulator with detailed
instructions, to use for 20 min 3-4 times daily and pro-
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phylactically before exposure to cold, for a period of 4
weeks.
Nerve conduction velocities
Measurements of nerve conduction velocities (NCV) were
performed with a DISA Neuromatic 2000, using surface
electrodes for stimulation and recording, at skin temperature
>30°C. Motor NCV was measured in the right median and
anterior peroneal nerves and sensory NCV in the right
median and sural nerves.
Results
Raynaud's phenomenon
Laser Doppler in the control group showed a baseline flux
with vasomotor oscillations with a frequency of 5-1Os-,
reflecting the normally occurring bursts of sympathetic vaso-
motor impulses. The flux level was about six units. After
submersion of the hand in cold water, there was a mean flux
reduction of 24%, with a mean restitution time of 1.5 min
before baseline flux was regained (Figure 1).
All the eight patients who had received CVB treatment,
described typical Raynaud's phenomenon that was first
observed 1-3 months after treatment. Six of them still
developed Raynaud's phenomenon on exposure to cold,
whereas the condition had improved in the other two. No
patients had trophical skin changes. None of the patients
with Raynaud's phenomenon had rheumatic diseases.
In the CVB treated patients, the mean flux level before
cold provocation was similar to the control group, with
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normal vasomotor oscillations. The mean flux reduction on
cold provocation was 61% (range 44-85%) with disappear-
ance of the vasomotor oscillations, and a mean restitution
time of >7 min (range 2- > 15 min) (Figure 2). In the
patients without chemotherapy the findings were similar to
the control group.
After 25 min TNS given to six patients, the flux reduction
after cold provocation was slightly less in two patients and
unchanged in four, whereas the restitution time was un-
changed in all. An immediate effect of TNS on peripheral
microcirculation could therefore not be demonstrated. After
4 weeks of 25 min TNS 3-4 times daily, none of the patients
could report a marked effect on the Raynaud's phenomena,
although three patients thought they occurred a little less
frequently.
Polyneuropathy
Of the eight patients with Raynaud's phenomenon, three had
no clinical or neurophysiological signs of polyneuropathy.
Five patients had pathological neurophysiological findings,
with clinical findings in four. The main symptoms were
numbness and paresthesia of the feet, and reduced flexion
and extension of the toes. The main clinical findings were
abolished achilles tendon reflexes and reduced distal percep-
tion of vibration and pain. All the five patients with poly-
neuropathy had pathological neurophysiological findings in
the sural nerve, with reduced sensory nerve action potential
amplitude in three, and no measurable potential in two
patients. In the other nerves the findings were few and
insignificant.
Discussion
Raynaud's phenomenon is divided into two pathophysio-
logical groups: (1) obstructive Raynaud's phenomenon, with
structural changes of the vessel walls and reduced lumen,
which is occluded by a normal vasoconstrictor response to
cold, and (2) vasospastic Raynaud's phenomenon, with nor-
mal caliber of the vessels (Keenan & Porter, 1983; Lafferty et
al., 1983).
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Figure 1 Laser Doppler flowmetry of three healthy controls,
showing capillary flux in the right index finger before and after
cold provocation with submersion of the hand in water holding
15°C for 2min (arrows).
Time
1 min
Figure 2 Laser Doppler flowmetry of three CVB-treated
patients, showing capillary flux in the right index finger before
and after submersion of the hand in water holding 15°C for 2 min
(arrows), showing an increased and prolonged vasospastic re-
sponse to cold compared to the normal controls.
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In the vasospastic Raynaud's phenomenon the sympathetic
vasoconstrictor response to cold is exaggerated and followed
by a prolonged period without the normal post sympathetic
vasodilatation. An increased activity in sympathetic vaso-
constrictor fibres or an increased sensitivity of a- adrenergic
receptors in the arteriolar walls have been suggested as
mechanisms for the vasoconstrictor component of the Ray-
naud's phenomenon. The lack of postsympathetic vasodilata-
tion may also be explained by an increased sympathetic tone.
However, an as yet poorly understood defect in the hista-
minergic vasodilating system has also been suggested, pos-
sibly caused by a reduction ofavailable tissue histamine. Oral
administration of Hl- and H2- Histamine blockers to normal
subjects has induced Raynaud's phenomenon, and supports
this theory (Lafferty et al., 1983). Others have found an
increased resistance to the vasodilator effects of prostaglan-
dines in patients with vasospastic Raynaud's phenomenon
(Horrobin et al., 1983).
In previous studies Raynaud's phenomenon has been
reported in about 30% of patients after CVB treatment
(Hansen et al., 1989; Vogelzang et al., 1981). This is in
accordance with the results of the questionnaire study from
which our patients were recruited.
In a previous study, finger systolic blood pressure was
measured in patients with Raynaud's phenomenon after
treatment with CVB (Hansen & Olsen, 1989). In that study
an enhanced reduction of finger systolic blood pressure was
demonstrated as a response to cooling, indicating an in-
creased vasospastic response to cold. However, the duration
of this response was not measured, and the method did not
allow a study of the vasomotor oscillations normally occur-
ing in the capillaries.
In our study all the patients who had received chemo-
therapy had normal digital blood flow with normal vasomotor
oscillations before cold provocation and an exaggerated and
markedly prolonged response to cold compared to the con-
trol groups, with disappearance of vasomotor oscillations,
emphasising the characteristics of a vasospastic type of
Raynaud's phenomenon.
In previous studies (Vogelzang, 1981) there has been no
significant difference in the frequency of neuropathy between
the patients with and without Raynaud's phenomenon. The
mechanisms for development of Raynaud's phenomena are
probably different from the pathophysiological mechanisms
of the polyneuropathy, as the Raynaud's phenomenon deve-
loped about 3-6 months after chemotherapy, when most of
the symptoms of autonomic dysfunction and polyneuropathy
had disappeared. In our study, three of the eight patients
with Raynaud's phenomenon had no evidence of polyneuro-
pathy. The number of patients in the present pilot study was,
however, too small for a statistical evaluation.
None of our patients had any convincing effect of TNS,
although this treatment has been reported to reduce the
vasospastic Raynaud's phenomenon in other studies, possibly
by an increased release of the neurotransmitter VIP (vaso-
active intestinal polypeptide) (Kaada et al., 1984). This sug-
gests that the Raynaud's phenomenon after cisplatin-based
chemotherapy may be caused by other pathophysiological
mechanisms.
In conclusion, increased and prolonged vasoconstrictor re-
sponse to cold, which can be measured by the laser Doppler
method, frequently develops after CVB treatment, causing
Raynaud's phenomenon of the vasospastic type. Further
pathophysiological mechanisms still remain obscure, and a
correlation with polyneuropathy as an etiological factor has
not been ascertained. As all the previous studies have been
retrospective, a prospective study with laser Doppler record-
ings before, during, and 6-12 months after chemotherapy
may give additional information of the development of Ray-
naud's phenomenon after combination chemotherapy.
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